Thursday, December 13, 2018
AstraZeneca initiated at SunTrust
SunTrust sees oncology fueling growth for AstraZeneca through 2022. SunTrust analyst John Boris initiated AstraZeneca with a Buy rating and $48 price target, saying oncology should fuel growth through 2022 — supported by label expansion of its in-line products and new launches — as well as growth accelerated by 2019 pipeline catalysts.
https://thefly.com/landingPageNews.php?id=2837051
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.